A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Histological confirmation of RCC with a clear-cell component, including participants
who may also have sarcomatoid features

- Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC
Stage IV) RCC

- No prior systemic therapy for RCC with the following exception:

i) One prior adjuvant or neoadjuvant therapy for completely resectable RCC if such
therapy did not include an agent that targets VEGF or VEGF receptors and if recurrence
occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy

Exclusion Criteria:

- Any active CNS metastases

- Any active, known or suspected autoimmune disease

- Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily
prednisone equivalent) or other immunosuppressive medications within 14 days of
randomization

Other protocol defined inclusion/exclusion criteria could apply